Immunotherapy as part of combinations for the treatment of cancer

International Immunopharmacology

Volumn 3, Issue 8, 2003, Pages 1051-1059

  Mitchell, Malcolm S ^a,b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Biological therapy; Chemotherapy; Immunomodulation; Immunosuppression; Vaccines

Indexed keywords

ALPHA2B INTERFERON; CANCER VACCINE; CARMUSTINE; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOKINE ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GLYCOPROTEIN GP 100; HISTAMINE; HLA A ANTIGEN; INTERLEUKIN 2; LEVAMISOLE; MELACINE; MELAN A; MELANOMA VACCINE; MELPHALAN; NAVELBINE; PACLITAXEL; REACTIVE OXYGEN METABOLITE; TAMOXIFEN; THERATOPE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ACTIVE IMMUNIZATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SYNTHESIS; HEAD AND NECK CANCER; HUMAN; IMMUNOSTIMULATION; INHIBITION KINETICS; LIVER METASTASIS; MELANOMA; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TOXICITY; TUMOR CELL;

EID: 0038307824     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00019-5     Document Type: Conference Paper

References (40)

1. Schwartz A., Gershon R.D. Regulation of in vitro cytotoxic T lymphocyte generation: III. Interactions or regulatory T cell subsets in suppressor and target populations. J. Mol. Cell. Immunol. 1:1984;237-252.
2. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P.et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194:2001;823-832.
3. Dong C., Juedes A.E., Temann U.A., Shresta S., Allison J.P., Ruddle N.H.et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 409:2001;97-101.
4. Thompson C.B., Allison J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity. 7:1997;445-450.
5. Mitchell M.S., Kan-Mitchell J., Kempf R.A., Harel W., Shau H., Lind S. Active specific immunotherapy of melanoma. Phase I trial of allogeneic melanoma lysates and a novel adjuvant. Cancer Res. 48:1988;5883-5893.
6. Berd D., Maguire H.J., Mastrangelo M.J. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res. 44:1984;5439-5443.
7. Ehrke M.J., Mihich E., Berd D., Mastrangelo M.J. Effects of anticancer drugs on the immune system in humans. Semin. Oncol. 16:1989;230-253.
8. Mescher M.F., Rogers J.D. Immunotherapy of established murine tumors with large multivalent immunogen and cyclophosphamide. J. Immunother. Emphasis Tumor Immunol. 19:1996;102-112.
9. MacLean G.D., Bowen-Yacyshyn M.B., Samuel J., Meikle A., Stuart G., Nation J.et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J. Immunother. 11:1992;292-305.
10. MacLean G.D., Reddish M., Koganty R., Longenecker B.M. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother. 19:1996;59-68.
11. Miles D.W., Towlson K.E., Graham R., Reddish M., Longenecker B.M., Taylor-Papadimitriou J.et al. A randomized phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. J. Cancer. 74:1996;1292-1296.
12. Sandmaier B.M., Oparin D.V., Holmberg L.A., Reddish M.A., MacLean G.D., Longenecker B.M. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J. Immunother. 22:1999;54-66.
13. Rosenberg S.A., Zhai Y., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M.et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90:1998;1894-1900.
14. van Elsas A., Hurwitz A.A., Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190:1999;355-366.
15. Hurwitz A.A., Foster B.A., Kwon E.D., Truong T., Choi E.M., Greenberg N.M.et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60:2000;2444-2448.
16. Hurwitz A.A., Yu T.F., Leach D.R., Allison J.P. CTLA-4 blockage synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. U. S. A. 95:1998;10067-10071.
17. Kwon E.D., Foster B.A., Hurwitz A.A., Madias C., Allison J.P., Greenberg N.M.et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA04) blockade immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 96:1999;15074-15079.
18. van Elsas A., Sutmuller R.P., Hurwitz A.A., Ziskin J., Villasenor J., Medema J.P.et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194:2001;481-489.
19. Mitchell M.S., Kemph R.A., Harel W., Shau H., Boswell W.D., Lind S.et al. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J. Clin. Oncol. 6:1988;409-424.
20. Atzpodien J., Korfer A., Franks C.R., Poliwoda H., Kirchner H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet. 335:1990;1509-1512.
21. Atzpodien J., Kirchner H. The out-patient use of recombinant human Interleukin-2 and interferon alfa-2b in advanced malignancies. Eur. J. Cancer. 27(Suppl. 4):1991;S88-S91.
22. Rosenberg S.A., Lotze M.T., Yang J.C., Linehan W.M., Seipp C., Calabro S.et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol. 7:1989;1863-1874.
23. Marincola F.M., White D.E., Wise A.P., Rosenberg S.A. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J. Clin. Oncol. 13:1995;1110-1122.
24. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L.et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J. Clin. Oncol. 17:1999;968-975.
25. Bukowski R.M., Olencki T., Wang Q., Peereboom D., Budd G.T., Elson P.et al. Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response. J. Immunother. 20:1997;301-311.
26. Clark J.I., Gaynor E.R., Martone B., Budds S.C., Manjunath R., Flanigan R.C.et al. Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma. Clin. Cancer Res. 5:1999;2374-2380.
27. Grimm E.A., Smid C.M., Lee J.J., Tseng C.H., Eton O., Buzaid A.C. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin. Cancer Res. 6:2000;3895-3903.
28. Capuron L., Ravaud A., Gualde N., Bosmans E., Dantzer R., Maes M.et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology. 26:2001;797-808.
29. Hellstrand K., Brune M., Dahlgren C., Hansson M., Hermodsson S., Lindner P.et al. Alleviating oxidative stress in cancer immunotherapy: a role for histamine? Med. Oncol. 17:2000;258-269.
30. Hellstrand K., Asea A., Dahlgren C., Hermodsson S. Histaminergic regulation of ND cells. Role of monocyte-derived reactive oxygen metabolites. J. Immunol. 153:1994;4940-4947.
31. Agarwala S.S., Glaspy J., O'Day S.J., Mitchell M., Gutheil J., Whitman E.et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J. Clin. Oncol. 20:2002;125-133.
32. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L.et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. 163:1999;1690-1695.
33. Wolmark N., Bryant J., Smith R., Grem J., Allegra C., Hyams D.et al. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J. Natl. Cancer Inst. 90:1998;1810-1816.
34. Legha S.S., Ring S., Eton O., Bedikian A., Buzaid A.C., Plager C.et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol. 16:1998;1752-1759.
35. Eton O., Legha S.S., Bedikian A.Y., Lee J.J., Buzaid A.C., Hodges C.et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J. Clin. Oncol. 20:2002;2045-2052.
36. Atzpodien J., Neuber K., Kamanabrou D., Fluck M., Brocker E.B., Neumann C.et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br. J. Cancer. 86:2002;179-184.
37. Dudley M.E., Wunderlich J., Nishimura M.I., Yu D., Yang J.C., Topalian S.L.et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24:2001;363-373.
38. Mitchell M.S., Darrah D., Yeung D., Halpern S., Wallace A., Voland J.et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J. Clin. Oncol. 20:2002;1075-1086.
39. Mitchell M.S., Press M.F. The role of immunohistochemistry and fluorescence in situ hybridization for Her2/neu in assessing the prognosis of breast cancer. Semin. Oncol. 26:1999;108-116.
40. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A.et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792.